Results 131 to 140 of about 540,096 (367)

Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer

open access: yesScientific Reports
HER2 overexpression/amplification (HER2+) occurs in approximately 15–20% of breast cancer (BC) and identifies a highly aggressive BC subtype. The cure rate of HER2 + BC has been significantly increased through recent clinical achievements; however, a non-
Lorenzo Castagnoli   +18 more
doaj   +1 more source

Platelets and platelet-derived extracellular vesicles: their role in lung cancer dissemination and premetastatic niche formation

open access: yesFrontiers in Immunology
Metastasis, the primary cause of cancer-related mortality, is sustained by complex interactions between tumor cells and host-derived factors. Extracellular vesicles, membrane-bound particles that mediate intercellular communication, have emerged as ...
Camilla Locatelli   +5 more
doaj   +1 more source

CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

open access: gold, 2023
Adi Diab   +22 more
openalex   +1 more source

MiR‐513a promotes human erythroid differentiation by modulating c‐Jun

open access: yesFEBS Open Bio, EarlyView.
During early human erythropoiesis, miR‐513a promoted erythroid differentiation in primary human CD34+ hematopoietic stem‐progenitor cells and human TF‐1 erythroleukemic cells by indirectly decreasing c‐Jun and phospho‐c‐Jun expression, which are associated with increased GATA1 expression.
MinJung Kim   +11 more
wiley   +1 more source

One size does not fit all: An in vitro evaluation of the effects of bezafibrate and medroxyprogesterone acetate on human SH‐SY5Y and U‐87 MG cancer cells

open access: yesFEBS Open Bio, EarlyView.
Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar   +4 more
wiley   +1 more source

MiRNAs: a call to arms that shapes the plasticity of tumor associated macrophages in breast cancer

open access: yesFrontiers in Immunology
Breast cancer (BC) remains a leading cause of cancer-related mortality, and a major contribution to tumor progression and resistance to therapies arise from tumor microenvironment (TME).
Valentina Fogazzi   +9 more
doaj   +1 more source

Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice

open access: yesFEBS Open Bio, EarlyView.
In a murine model of myocardial ischemia and reperfusion (MI/R), the CD36 azapeptide ligand MPE‐298 reduces cardiac injury and transiently lowers left ventricular long‐chain fatty acids (LCFAs) accumulation 3 h after reperfusion, accompanied by a decrease of oxidative stress and inflammation‐associated genes' expression in the heart and adipose tissue.
Jade Gauvin   +12 more
wiley   +1 more source

Dysbiosis and extraintestinal cancers

open access: yesJournal of Experimental & Clinical Cancer Research
The gut microbiota plays a crucial role in safeguarding host health and driving the progression of intestinal diseases. Despite recent advances in the remarkable correlation between dysbiosis and extraintestinal cancers, the underlying mechanisms are yet
Ruishan He   +7 more
doaj   +1 more source

Iberverin Downregulates GPX4 and SLC7A11 to Induce Ferroptotic Cell Death in Hepatocellular Carcinoma Cells

open access: yesBiomolecules
Ferroptosis, a recently elucidated style of regulated cell death, has emerged as a significant area of investigation in cancer biology. Natural active compounds that have anti-cancer effects are promising candidates for cancer prevention.
Haoying Yang   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy